CN1178675C - Toxin-discharging liver-fortifying medicine - Google Patents
Toxin-discharging liver-fortifying medicine Download PDFInfo
- Publication number
- CN1178675C CN1178675C CNB00113227XA CN00113227A CN1178675C CN 1178675 C CN1178675 C CN 1178675C CN B00113227X A CNB00113227X A CN B00113227XA CN 00113227 A CN00113227 A CN 00113227A CN 1178675 C CN1178675 C CN 1178675C
- Authority
- CN
- China
- Prior art keywords
- radix
- root
- medicine
- present
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a toxin-expelling and liver-fortifying medicine selected from artemisia capillaris, gardenia, rhubarb, giant knotweed rhizome, baical skullcap root, oldenlandia diffusa, licorice root, tuckahoe, white atractylodes rhizome, Chinese thorowax, white paeony root, cortex moutan, unprocessed rehmannia root, curcuma root, rhizoma coridalis, chicken's gizzard-membrane, fried turtle shell, prepared fleece-flower root and xisha according to a certain proportion; after being pulverized and ground, a proper amount of blending agent is added to the materials to be blended uniformly, and then the medicine of the present invention is prepared by packaging. The medicine of the present invention is pure traditional Chinese medicine preparation, and has no toxic or side effect. The present invention has the functions of benefiting the liver and gall, preventing bacteria, expelling toxins, removing blood clots, alleviating pain, softening and resolving hard mass, enhancing the immunological function of the human body, resisting, disturbing and suppressing the growth of early hepatoma carcinoma cells, and softening hepatic tissue function, and can treat various liver and gallbladder diseases. The present invention treats both manifestation and root cause of disease, which takes detoxication as basis and emphasizes body-building and immunological function enhancement, and has obvious therapeutic effect.
Description
The present invention relates to a kind of medical drugs, particularly a kind of medicine for the treatment of liver, biliary diseases.
Liver, biliary diseases are commonly encountered diseases, the frequently-occurring diseases of serious harm health, but existing treatment medicine effect is single, curative effect is undesirable, and toxic and side effects is big.
The purpose of this invention is to provide a kind for the treatment of both the principal and secondary aspects of a disease, good effect, can treat the medicine of multiple liver, gallbladder disease disease.
Technical solution of the present invention is such: the treatment liver, in the crude drug of the medicine of biliary diseases, press Herba Artemisiae Scopariae 10-30g, Fructus Gardeniae 5-15g, Radix Et Rhizoma Rhei 5-15g, Rhizoma Polygoni Cuspidati 5-15g, Radix Scutellariae 5-15g, Herba Hedyotidis Diffusae 25-50g, Radix Glycyrrhizae 15-30g, Poria 15-30g, Rhizoma Atractylodis Macrocephalae 10-30g, Radix Bupleuri 5-15g, Radix Paeoniae Alba 5-15g, Cortex Moutan 5-15g, Radix Rehmanniae 0-15g, Radix Curcumae 5-15g, Rhizoma Corydalis 0-15g, Endothelium Corneum Gigeriae Galli 5-25g, Carapax Trionycis (processed) 0-25g, Radix Polygoni Multiflori Preparata 0-30g, Fructus Amomi 5-15g is that the ratio of potion is chosen, through pulverizing, after milling, add an amount of blending agents blending evenly, packing and produce product.
Embodiment 1: in the crude drug, be that the ratio of potion is chosen in Herba Artemisiae Scopariae 15g, Fructus Gardeniae 10g, Radix Et Rhizoma Rhei 10g, Rhizoma Polygoni Cuspidati 10g, Radix Scutellariae 10g, Herba Hedyotidis Diffusae 30g, Radix Glycyrrhizae 20g, Poria 20g, Rhizoma Atractylodis Macrocephalae 15g, Radix Bupleuri 10g, Radix Paeoniae Alba 10g, Cortex Moutan 10g, Radix Rehmanniae 15g, Radix Curcumae 10g, Rhizoma Corydalis 10g, Endothelium Corneum Gigeriae Galli 10g, Carapax Trionycis (processed) 15g, Radix Polygoni Multiflori Preparata 20g, Fructus Amomi 5g.The above-mentioned raw materials medicine being cleaned, dried, after pulverizing, being milled into powder, add the blending of 250g Mel and evenly make pill, bottles and produces product in dry back.
Embodiment 2: the choosing, process of crude drug with embodiment 1, and the ratio that adds 2500 milliliters in water in potion crude drug powder adds water-cooled soaked 2 hours, and reheat kept 0.5 hour to boiling, and filtered with 100 mesh sieve cloth, was cooled to room temperature and went into refrigerator cold-storage; The ratio that adds 2000 milliliters of 90% ethanol in potion crude drug filtering residue adds ethanol and quenches and get 7 days, jolting every day 3 times, each about 5 minutes, pressure filtration then merges the filtrate heating evaporation twice, is dried to powder, add the starch tabletting again and make tablet or capsule, packing and produce product.
Embodiment 3: choosing, process with embodiment 1 of crude drug is made into injection with the crude drug powder by the existing technology distillation for preparing injection.
Embodiment 4: choosing, process with embodiment 1 of crude drug is made into oral liquid with the technology by existing preparation oral liquid after the crude drug powder adding proper honey.
The present invention is owing to adopt above prescription, and the medicine of producing is pure form of Chinese drug, has no side effect, and mouthfeel is good, has the liver heat removing function of gallbladder promoting, antibiotic toxin expelling, blood-activating analgetic, hard masses softening and resolving, strengthen body immune function, opposing, interference, the growth of inhibition early hepatocarcinoma cell, softening hepatic tissue effect.The treating acute and chronic icterohepatitis, hepatitis B, early stage liver cirrhosis, early hepatocarcinoma; Acute and chronic cholecystitis, the silt sample stasis of blood is amassed the type liver and bile stone, operation back retained calculus and recurrent cholelithiasis.Treating both the principal and secondary aspects of a disease, based on toxin expelling, focus on be healthy and strong, raise immunity, curative effect is obvious.Use this clinical drug treatment acute and chronic icterohepatitis 188 examples, it is 15-46 days that icteric index, glutamate pyruvate transaminase recover normally, and average 30 days, patient's subjective symptoms was generally taken medicine and promptly obviously alleviated in 3-7 days, wherein 9 examples are because of outside the other reasons therapy discontinued, and all the other 179 examples are all cured.Treatment hepatitis B 112 examples, except that 10 examples shift the treatment midway, all the other 86 examples " great three positive " all the moon transfer " small three positive ", whole cloudy commentaries on classics of 16 examples to, and wherein 11 examples are 60 days, and 58 examples are 180 days, and 33 examples are 270 days.Treatment early stage liver cirrhosis 15 examples are wherein cured 8 examples, effective 5 examples, invalid 2 examples, and treatment time is 180-450 days.Treat former massive hepatocarcinoma 3 examples, effective 3 examples were on average taken medicine 45 days, and clinical symptoms jaundice, pain relief, appetite increase.Treatment acute and chronic cholecystitis 66 examples were taken medicine 3-7 days, and symptom obviously alleviates or disappears, and takes medicine 15-45 days, and average out to 30 days was followed up a case by regular visits to after 6 months, did not see recurrence.The long-pending type liver and bile stone of the treatment silt sample stasis of blood, operation back retained calculus, recurrent cholelithiasis 12 examples were taken medicine 3-7 days, and symptom obviously changes or disappears, and on average took medicine 90 days, and 8 routine B ultrasonic check hepatic ducts and the no abnormal pathology of gallbladder find that 4 example promptings are clearly better.
Claims (1)
1, a kind of treatment liver, the medicine of biliary diseases, it is characterized in that it being: Tarragon 10-30g with following raw material medicaments, Fructus Gardeniae 5-15g, Radix Et Rhizoma Rhei 5-15g, Rhizoma Polygoni Cuspidati 5-15g, Radix Scutellariae 5-15g, Herba Hedyotidis Diffusae 25-50g, Radix Glycyrrhizae 15-30g, Poria 15-30g, Rhizoma Atractylodis Macrocephalae 10-30g, Radix Bupleuri 5-15g, Radix Paeoniae Alba 5-15g, Cortex Moutan 5-15g, Radix Rehmanniae 0-15g, Radix Curcumae 5-15g, Rhizoma Corydalis 0-15g, Endothelium Corneum Gigeriae Galli 5-25g, Carapax Trionycis (processed) 0-25g, Radix Polygoni Multiflori Preparata 0-30g, Fructus Amomi 5-15g is that the ratio of potion is chosen, through pulverizing, after milling, add an amount of blending agents blending evenly, packing promptly.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB00113227XA CN1178675C (en) | 2000-01-12 | 2000-01-12 | Toxin-discharging liver-fortifying medicine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB00113227XA CN1178675C (en) | 2000-01-12 | 2000-01-12 | Toxin-discharging liver-fortifying medicine |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1303692A CN1303692A (en) | 2001-07-18 |
CN1178675C true CN1178675C (en) | 2004-12-08 |
Family
ID=4583032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB00113227XA Expired - Fee Related CN1178675C (en) | 2000-01-12 | 2000-01-12 | Toxin-discharging liver-fortifying medicine |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1178675C (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1326537C (en) * | 2005-09-27 | 2007-07-18 | 薛海川 | Chinese medicine infusion granule for treating appendicitis |
CN101579414B (en) * | 2008-05-15 | 2011-04-20 | 北京北大维信生物科技有限公司 | Medicinal composition for treating biliary calculus |
CN103585323B (en) * | 2012-08-14 | 2015-12-09 | 覃德光 | The Chinese medicine preparation for the treatment of hepatitis B virus great three positive |
CN102764337B (en) * | 2012-08-20 | 2014-04-09 | 马驰 | Traditional Chinese medicine composition for curing hepatitis B |
CN103405726A (en) * | 2013-08-28 | 2013-11-27 | 李新民 | Formula of great soup for soothing liver, dispelling depression, detoxifying and nourishing spirit |
CN103599495A (en) * | 2013-12-06 | 2014-02-26 | 陆思选 | Chinese medicinal composition for treatment of hepatitis B |
CN104399012B (en) * | 2014-12-16 | 2017-12-26 | 刘尚勤 | A kind of Chinese medicine composition for primary liver cancer |
CN104784641A (en) * | 2015-04-27 | 2015-07-22 | 陈玉龙 | Traditional Chinese medicine preparation for treating liver cirrhosis disease |
CN106039144A (en) * | 2016-06-29 | 2016-10-26 | 韩秀山 | Traditional Chinese medicine composition for treating chronic hepatitis B, regulating qi and blood and removing toxic matters |
CN106074961A (en) * | 2016-06-29 | 2016-11-09 | 韩秀山 | Acute hepatitis B adjusts the Chinese medicine composition of QI and blood toxin expelling |
CN106309875A (en) * | 2016-09-20 | 2017-01-11 | 陈亚平 | Traditional Chinese medicine with efficacies of detoxifying and skin moistening |
CN107412398A (en) * | 2017-08-02 | 2017-12-01 | 孙福能 | Treat the Chinese medicine composition of hepatopathy |
-
2000
- 2000-01-12 CN CNB00113227XA patent/CN1178675C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1303692A (en) | 2001-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102133378B (en) | Medicament for treating breast cancer | |
CN1178675C (en) | Toxin-discharging liver-fortifying medicine | |
CN1065134C (en) | Quick-acting preparation for litholysis | |
CN1150928C (en) | Medicine for curing cancers and its preparation method | |
CN101361919B (en) | Traditional Chinese medicine preparation for treating various skin pyogenic infection, inflammation, trauma | |
CN1436564A (en) | Liver cancer treating medicine and its prepn | |
CN102091311B (en) | Traditional Chinese medicinal composition for treating rheumatoid arthritis and preparation method thereof | |
CN1181849C (en) | Gastropathy treating Chinese medicine | |
CN104524159A (en) | Pharmaceutical composition for treating hyperplasia of mammary glands | |
CN1228063C (en) | Medicine for treating liver disease | |
CN104042925A (en) | Traditional Chinese medicinal composition for treating gout and preparation method thereof | |
CN104189764A (en) | Traditional Chinese medicinal preparation for treating intervention postoperative fever | |
CN1063960C (en) | Chinese medicine for treating hepatitis B | |
CN1060349C (en) | Menstruation-regulating and speckle-removing capsule and preparation thereof | |
CN104547425A (en) | Decoction medicine for treating paralytic strabismus and preparation method pf decoction medicine | |
CN103948875A (en) | Medicine for treating hepatitis B and preparation method thereof | |
CN103656199B (en) | A kind of Chinese medicine for the treatment of deficiency of kidney yin syndrome cough | |
CN116350731B (en) | Formula for clearing heat, removing dampness and relieving arthralgia as well as preparation and application thereof | |
CN1559471A (en) | Chinese medicine/preparation | |
CN105327024A (en) | Traditional Chinese medicine preparation for treating rheumatoid arthritis | |
CN104147515A (en) | Oral medicine for treating stomach cancer and preparation method of medicine | |
CN1413662A (en) | Decoction for positive reaction of hepatitis B transformation to negative | |
CN100479852C (en) | Chinese medicinal capsule for treating AIDS and preparation technology thereof | |
CN102847069A (en) | Traditional Chinese drug composition for treating angioneurotic headache | |
CN103830622A (en) | Traditional Chinese medicine composition for treating gastric erosion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |